{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T10:02:28Z","timestamp":1790848948288,"version":"4.1.0"},"reference-count":105,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.drudis.2026.104663","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T16:55:11Z","timestamp":1775494511000},"page":"104663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Addressing delivery and resistance issues of CDK4\/6 inhibitors as cancer therapeutics"],"prefix":"10.1016","volume":"31","author":[{"given":"Kshitiz","family":"Luthra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalla Usha","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Pada","family":"Datta Chigurupati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5275-8065","authenticated-orcid":false,"given":"Neelesh Kumar","family":"Mehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2026.104663_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.drudis.2026.104663_b0010","unstructured":"Global Cancer Observatory. Statistics at a Glance, India, 2022. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/356-india-fact-sheet.pdf [Accessed April 1, 2026]."},{"key":"10.1016\/j.drudis.2026.104663_b0015","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.drudis.2026.104663_b0020","series-title":"The Cell: A Molecular Approach","author":"Cooper","year":"2000"},{"key":"10.1016\/j.drudis.2026.104663_b0025","first-page":"1","article-title":"Signaling pathways in cancer metabolism: mechanisms and therapeutic targets","volume":"8","author":"You","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.drudis.2026.104663_b0030","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/cells10030659","article-title":"Signaling pathways in cancer: therapeutic targets, combinatorial treatments, and new developments","volume":"10","author":"Yip","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.drudis.2026.104663_b0035","unstructured":"National Cancer Institute. Types of Cancer Treatment. www.cancer.gov\/about-cancer\/treatment\/types [Accessed April 1, 2026]."},{"key":"10.1016\/j.drudis.2026.104663_b0040","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.semcancer.2023.12.002","article-title":"Beyond cell cycle regulation: the pleiotropic function of CDK4 in cancer","volume":"98","author":"Ziegler","year":"2024","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.drudis.2026.104663_b0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154854","article-title":"The pathophysiology of the cell cycle in cancer and treatment strategies using various cell cycle checkpoint inhibitors","volume":"251","author":"Almalki","year":"2023","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.drudis.2026.104663_b0050","article-title":"Role of retinoblastoma protein family (Rb\/p105 and Rb2\/p130) expression in the histopathological classification of borderline ovarian tumors","volume":"7","author":"Masciullo","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.drudis.2026.104663_b0055","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01032-22","article-title":"Retinoblastoma protein is required for Epstein-Barr virus replication in differentiated epithelia","volume":"97","author":"Myers","year":"2023","journal-title":"J Virol"},{"key":"10.1016\/j.drudis.2026.104663_b0060","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201948460","article-title":"PHF6 promotes non\u2010homologous end joining and G2 checkpoint recovery","volume":"21","author":"Warmerdam","year":"2020","journal-title":"EMBO Rep"},{"key":"10.1016\/j.drudis.2026.104663_b0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.semcdb.2021.06.009","article-title":"Spindle assembly checkpoint activation and silencing at kinetochores","volume":"117","author":"Lara-Gonzalez","year":"2021","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.drudis.2026.104663_b0070","doi-asserted-by":"crossref","DOI":"10.1111\/acel.13489","article-title":"Age-dependent integrity of the meiotic spindle assembly checkpoint in females requires Aurora kinase B","volume":"20","author":"Blengini","year":"2021","journal-title":"Aging Cell"},{"key":"10.1016\/j.drudis.2026.104663_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108929","article-title":"Molecular mechanisms of APC\/C release from spindle assembly checkpoint inhibition by APC\/C SUMOylation","volume":"34","author":"Yatskevich","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.drudis.2026.104663_b0080","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.semcancer.2022.12.006","article-title":"CDK inhibitors from past to present: a new wave of cancer therapy","volume":"88","author":"Mughal","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.drudis.2026.104663_b0085","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","article-title":"Treating cancer with selective CDK4\/6 inhibitors","volume":"13","author":"O\u2019Leary","year":"2016","journal-title":"Nat Rev Clin Onco"},{"key":"10.1016\/j.drudis.2026.104663_b0090","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Onco"},{"key":"10.1016\/j.drudis.2026.104663_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00880-8","article-title":"The application and prospect of CDK4\/6 inhibitors in malignant solid tumors","volume":"13","author":"Du","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.drudis.2026.104663_b0100","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1158\/0008-5472.CAN-15-0728","article-title":"Early adaptation and acquired resistance to CDK4\/6 inhibition in estrogen receptor-positive breast cancer","volume":"76","author":"Herrera-Abreu","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.drudis.2026.104663_b0105","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejmech.2019.03.064","article-title":"Third-generation CDK inhibitors: a review on the synthesis and binding modes of palbociclib, ribociclib and abemaciclib","volume":"172","author":"Poratti","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.drudis.2026.104663_b0110","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","article-title":"Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.drudis.2026.104663_b0115","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1016\/S1470-2045(23)00360-1","article-title":"Dalpiciclib in advanced breast cancer: introducing CDK4\/6 inhibitors as a first-line treatment might not be the best strategy","volume":"24","author":"Hindi\u00e9","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.drudis.2026.104663_b0120","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1158\/2159-8290.CD-20-1554","article-title":"CDK4\/6 inhibition promotes antitumor immunity through the induction of T-cell memory","volume":"11","author":"Lelliott","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.drudis.2026.104663_b0125","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104663_b0130","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Richard","year":"2016","journal-title":"N Eng J Med"},{"key":"10.1016\/j.drudis.2026.104663_b0135","doi-asserted-by":"crossref","first-page":"41794","DOI":"10.18632\/oncotarget.5993","article-title":"Palbociclib inhibits epithelial-mesenchymal transition and metastasis in breast cancer via c-Jun\/COX-2 signaling pathway","volume":"6","author":"Qin","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.drudis.2026.104663_b0140","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon","year":"2020","journal-title":"N Eng J Med"},{"key":"10.1016\/j.drudis.2026.104663_b0145","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Eng J Med"},{"key":"10.1016\/j.drudis.2026.104663_b0150","unstructured":"DailyMed. IBRANCE: Palbociclib Capsule. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=e0e6412f-50b4-4fd4-9364-62818d121a07 [Accessed April 1, 2026]."},{"key":"10.1016\/j.drudis.2026.104663_b0155","unstructured":"DailyMed. KISQALI: Ribociclib Tablet, Film Coated. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=aaeaef94-f3f5-4367-8ea2-b181d7be2da8 [Accessed April 1, 2026]."},{"key":"10.1016\/j.drudis.2026.104663_b0160","unstructured":"DailyMed. VERZENIO: Abemaciclib Tablet. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=be4bc0de-0fdc-4d46-8d25-be43c79e6a06 [Accessed April 1, 2026]."},{"key":"10.1016\/j.drudis.2026.104663_b0165","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-021-00271-2","article-title":"A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4\/6 inhibitor in Chinese patients with advanced breast cancer","volume":"9","author":"Zhang","year":"2021","journal-title":"Biomark Res"},{"key":"10.1016\/j.drudis.2026.104663_b0170","unstructured":"G1 Therapeutics. NCT03455829: G1T38, a CDK 4\/6 Inhibitor, in Combination With Osimertinib in EGFR-Mutant Non-Small Cell Lung Cancer. https:\/\/clinicaltrials.gov\/study\/NCT03455829?intr=G1T38&tab=results&rank=1#more-information [Accessed April 1, 2026]."},{"key":"10.1016\/j.drudis.2026.104663_b0175","doi-asserted-by":"crossref","first-page":"S395","DOI":"10.1016\/j.annonc.2025.08.943","article-title":"520P long-term safety and efficacy of first-line atirmociclib + letrozole for the treatment of patients with HR+\/HER2\u2212 metastatic breast cancer (mBC)","volume":"36","author":"Yap","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2026.104663_b0180","unstructured":"Pfizer. NCT05431153: A Study to Investigate the Effect of Tablet Formulation and Food on PF-07104091 in Healthy Participants https:\/\/clinicaltrials.gov\/study\/nct05431153?intr=pf-07104091&rank=4&tab=study [Accessed April 1, 2026]."},{"key":"10.1016\/j.drudis.2026.104663_b0185","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2147\/DDDT.S137783","article-title":"Abemaciclib: a CDK4\/6 inhibitor for the treatment of HR+\/HEeR2- advanced breast cancer","volume":"12","author":"Corona","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.drudis.2026.104663_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104686","article-title":"A unique CDK4\/6 inhibitor: current and future therapeutic strategies of abemaciclib","volume":"156","author":"Chong","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.drudis.2026.104663_b0195","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2026.104663_b0200","doi-asserted-by":"crossref","first-page":"248","DOI":"10.5306\/wjco.v5.i3.248","article-title":"Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer","volume":"5","author":"Zhao","year":"2014","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104663_b0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41523-023-00523-4","article-title":"An emerging generation of endocrine therapies in breast cancer: a clinical perspective","volume":"9","author":"Patel","year":"2023","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.drudis.2026.104663_b0210","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212579","article-title":"Palbociclib in metastatic breast cancer: current evidence and real-life data","volume":"8","author":"Serra","year":"2019","journal-title":"Drugs Context"},{"key":"10.1016\/j.drudis.2026.104663_b0215","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1177\/1060028015602273","article-title":"Palbociclib: a novel cyclin-dependent kinase inhibitor for hormone receptor-positive advanced breast cancer","volume":"49","author":"Mangini","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.drudis.2026.104663_b0220","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.4103\/0973-1482.168988","article-title":"Palbociclib: a new hope in the treatment of breast cancer","volume":"12","author":"Palanisamy","year":"2016","journal-title":"J Cancer Res Ther"},{"key":"10.1016\/j.drudis.2026.104663_b0225","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.drudis.2026.104663_b0230","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.drudis.2026.104663_b0235","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N Eng J Med"},{"key":"10.1016\/j.drudis.2026.104663_b0240","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1021\/acs.molpharmaceut.2c00545","article-title":"Use of Gastrointestinal simulator, mass transport analysis, and absorption simulation to investigate the impact of pH modifiers in mitigating weakly basic drugs\u2019 performance issues related to gastric pH: palbociclib case study","volume":"20","author":"Kuminek","year":"2023","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drudis.2026.104663_b0245","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/978-3-030-88719-3_3","article-title":"Solid-state techniques for improving solubility","volume":"50","author":"Jara","year":"2022","journal-title":"AAPS Series"},{"key":"10.1016\/j.drudis.2026.104663_b0250","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.3390\/molecules23071719","article-title":"Salts of therapeutic agents: chemical, physicochemical, and biological considerations","volume":"23","author":"Gupta","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2026.104663_b0255","unstructured":"David L, Thomas B. Improving API Solubility by Salt and Cocrystal Formation. www.sigmaaldrich.com\/deepweb\/assets\/sigmaaldrich\/marketing\/global\/documents\/635\/358\/improving-api-solubility-wp12169en-mk.pdf [Accessed April 1, 2026]."},{"key":"10.1016\/j.drudis.2026.104663_b0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.137756","article-title":"Improving dissolution rate and solubility of palbociclib salts\/cocrystal for anticancer efficacy","volume":"1305","author":"Allu","year":"2024","journal-title":"J Mol Struct"},{"key":"10.1016\/j.drudis.2026.104663_b0265","unstructured":"Svatora P, et al. Zentiva. Solid forms of palbociclib salts. WO2016127963A1."},{"key":"10.1016\/j.drudis.2026.104663_b0270","unstructured":"Beylin VG, et al. Warner Lambert Co. Isethionate salt of a selective CDK4 inhibitor. US20080021037A1."},{"key":"10.1016\/j.drudis.2026.104663_b0275","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1021\/acs.oprd.6b00071","article-title":"Palbociclib commercial manufacturing process development. part iii. deprotection followed by crystallization for API particle property control","volume":"20","author":"Chekal","year":"2016","journal-title":"Org Process Res Dev"},{"key":"10.1016\/j.drudis.2026.104663_b0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2023.135101","article-title":"Synthesis and structural characterization of a novel palbociclib-kaempferol cocrystal with improved tabletability and synergistic antitumor activity","volume":"1281","author":"Zhou","year":"2023","journal-title":"J Mol Struct"},{"key":"10.1016\/j.drudis.2026.104663_b0285","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/pharmaceutics14010023","article-title":"Two novel palbociclib-resorcinol and palbociclib-orcinol cocrystals with enhanced solubility and dissolution rate","volume":"14","author":"Duan","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.drudis.2026.104663_b0290","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1021\/acs.molpharmaceut.8b01229","article-title":"transformations between co-amorphous and co-crystal systems and their influence on the formation and physical stability of co-amorphous systems","volume":"16","author":"Wu","year":"2019","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drudis.2026.104663_b0295","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1039\/C8RA09710K","article-title":"Co-amorphous palbociclib\u2013organic acid systems with increased dissolution rate, enhanced physical stability and equivalent biosafety","volume":"9","author":"Zhang","year":"2019","journal-title":"RSC Adv"},{"key":"10.1016\/j.drudis.2026.104663_b0300","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1021\/acs.molpharmaceut.4c01224","article-title":"Investigation of a palbociclib and naringin co-amorphous system to ameliorate anticancer potential: insights on in silico modeling, physicochemical characterization, ex vivo permeation, and in vitro efficacy","volume":"22","author":"Tanmoy","year":"2025","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drudis.2026.104663_b0305","first-page":"217","article-title":"Injectable formulations of poorly water-soluble drugs","volume":"50","author":"O\u2019Mary","year":"2022","journal-title":"AAPS"},{"key":"10.1016\/j.drudis.2026.104663_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2024.124458","article-title":"Fabrication of \u03b2-cyclodextrin and 2-hydroxypropyl-\u03b2-cyclodextrin inclusion complexes of palbociclib: physicochemical characterization, solubility enhancement, in -silico studies, in vitro assessment in MDA-MB-231 cell line","volume":"399","author":"Paul","year":"2024","journal-title":"J Mol Liq"},{"key":"10.1016\/j.drudis.2026.104663_b0315","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.1024143","article-title":"Polymeric nanoparticles\u2014promising carriers for cancer therapy","volume":"10","author":"Xiao","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.drudis.2026.104663_b0320","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.msec.2015.11.067","article-title":"Polymeric nanoparticles for targeted drug delivery system for cancer therapy","volume":"60","author":"Masood","year":"2016","journal-title":"Mat Sci Eng: C"},{"key":"10.1016\/j.drudis.2026.104663_b0325","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1021\/acs.molpharmaceut.3c01086","article-title":"Redox-sensitive poly(lactic-co-glycolic acid) nanoparticles of palbociclib: development, ultrasound\/photoacoustic imaging, and smart breast cancer therapy","volume":"21","author":"Dhamija","year":"2024","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drudis.2026.104663_b0330","doi-asserted-by":"crossref","first-page":"34343","DOI":"10.1021\/acsami.3c03184","article-title":"Chitosan-g-estrone nanoparticles of palbociclib vanished hypoxic breast tumor after targeted delivery: development and ultrasound\/photoacoustic imaging","volume":"15","author":"Mehata","year":"2023","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.drudis.2026.104663_b0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.matdes.2022.111365","article-title":"Thermo-sensitive hydrogel-mediated locally sequential release of doxorubicin and palbociclib for chemo-immunotherapy of osteosarcoma","volume":"224","author":"Li","year":"2022","journal-title":"Mater Des"},{"key":"10.1016\/j.drudis.2026.104663_b0340","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.ejpb.2014.09.013","article-title":"Combinatorial delivery of crizotinib\u2013palbociclib\u2013sildenafil using TPGS-PLA micelles for improved cancer treatment","volume":"88","author":"De Melo-Diogo","year":"2014","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.drudis.2026.104663_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2025.113934","article-title":"Antibody-mediated ratiometric delivery of FLT3 and CDK4\/6 dual inhibitors for targeted treatment of acute myeloid leukemia","volume":"384","author":"Zhai","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2026.104663_b0350","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jconrel.2023.01.079","article-title":"Rational design of poly-L-glutamic acid-palbociclib conjugates for pediatric glioma treatment","volume":"355","author":"Melnyk","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2026.104663_b0355","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1420174","article-title":"Exploring pharmacokinetic variability of palbociclib in HR+\/HER2- metastatic breast cancer: a focus on age, renal function, and drug\u2013gene interactions","volume":"15","author":"Peruzzi","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.drudis.2026.104663_b0360","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1021\/acs.molpharmaceut.4c01122","article-title":"Development and preclinical assessment of a palbociclib nanostructured lipid carrier for potential breast cancer management","volume":"22","author":"Nehal","year":"2025","journal-title":"Mol Pharm"},{"key":"10.1016\/j.drudis.2026.104663_b0365","article-title":"Palbociclib-letrozole loaded solid self-nano emulsifying drug delivery system for oral treatment of breast cancer: In-vitro and In-vivo characterization","volume":"104","author":"Galatage","year":"2025","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.drudis.2026.104663_b0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125907","article-title":"Exosomes fused liposomes: formulation, stability studies and theranostic evaluation for breast cancer applications","volume":"682","author":"Verma","year":"2025","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2026.104663_b0375","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-17996-7","article-title":"Use of ratiometrically designed nanocarrier targeting CDK4\/6 and autophagy pathways for effective pancreatic cancer treatment","volume":"11","author":"Ji","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104663_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2025.145155","article-title":"Folate-targeted pH-sensitive albumin nanoparticles loaded with Baicalin enhance tamoxifen efficacy in estrogen receptor alpha-positive breast cancer","volume":"318","author":"Li","year":"2025","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2026.104663_b0385","article-title":"Engineering nanoparticle communication in living systems by stigmergy: an application to enhance antitumor therapy in triple-negative breast cancer","volume":"48","author":"Estepa","year":"2023","journal-title":"Nano Today"},{"key":"10.1016\/j.drudis.2026.104663_b0390","article-title":"Dual responsive hydroxyapatite capped mesoporous silica nanoparticles for controlled delivery of palbociclib to treat osteosarcoma","volume":"82","author":"Heydari","year":"2023","journal-title":"J Drug Deliv Sci Technol"},{"key":"10.1016\/j.drudis.2026.104663_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.128821","article-title":"Design, development, and evaluation of CDK-4\/6 inhibitor loaded 4-carboxy phenyl boronic acid conjugated pH-sensitive chitosan lecithin nanoparticles in the management of breast cancer","volume":"258","author":"Pooja","year":"2024","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2026.104663_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123787","article-title":"Targeted delivery and apoptosis induction of CDK-4\/6 inhibitor loaded folic acid decorated lipid-polymer hybrid nanoparticles in breast cancer cells","volume":"651","author":"Rajana","year":"2024","journal-title":"Int J Pharm"},{"key":"10.1016\/j.drudis.2026.104663_b0405","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jconrel.2024.12.067","article-title":"Self-assembled natural triterpenoids for the delivery of cyclin-dependent kinase 4\/6 inhibitors to enhance cancer chemoimmunotherapy","volume":"378","author":"Zhang","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2026.104663_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcis.2025.138203","article-title":"Engineering an advanced multicomponent pentacyclic triterpenoid nanoplatform for synergistic co-delivery of cyclin-dependent kinase 4\/6 inhibitors to enhance cancer chemoimmunotherapy","volume":"699","author":"Zhou","year":"2025","journal-title":"J Colloid Interface Sci"},{"key":"10.1016\/j.drudis.2026.104663_b0415","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.3390\/ijms20102428","article-title":"The L-type amino acid transporter LAT1\u2014an emerging target in cancer","volume":"20","author":"H\u00e4fliger","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.drudis.2026.104663_b0420","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10637-023-01409-9","article-title":"Targeted delivery of liposomal ribociclib to SLC7A5 transporters in breast cancer cells","volume":"42","author":"Afsharzadeh","year":"2024","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.drudis.2026.104663_b0425","article-title":"Immobilized doxorubicin and ribociclib carbamate linkers encaged in surface modified cubosomes spatially target tumor reductive environment to enhance antitumor efficacy","volume":"155","author":"Sharma","year":"2023","journal-title":"Biomater Adv"},{"key":"10.1016\/j.drudis.2026.104663_b0430","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1021\/acs.biomac.1c01076","article-title":"Amalgamated microneedle array bearing ribociclib-loaded transfersomes eradicates breast cancer via CD44 targeting","volume":"23","author":"Sharma","year":"2022","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.drudis.2026.104663_b0435","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6009309","article-title":"Ribociclib nanostructured lipid carrier aimed for breast cancer: formulation optimization, attenuating in vitro specification, and in vivo scrutinization","volume":"2022","author":"Sartaj","year":"2022","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.drudis.2026.104663_b0440","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1080\/1061186X.2022.2104292","article-title":"Combinatorial delivery of ribociclib and green tea extract mediated nanostructured lipid carrier for oral delivery for the treatment of breast cancer synchronising in silico, in vitro, and in vivo studies","volume":"30","author":"Sartaj","year":"2022","journal-title":"J Drug Target"},{"key":"10.1016\/j.drudis.2026.104663_b0445","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2021.115574","article-title":"Design and development of polymeric micelles as nanocarriers for anti-cancer ribociclib drug","volume":"329","author":"Fei","year":"2021","journal-title":"J Mol Liq"},{"key":"10.1016\/j.drudis.2026.104663_b0450","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ijbiomac.2022.06.095","article-title":"Redox responsive polymeric micelles of gellan gum\/abietic acid for targeted delivery of ribociclib","volume":"215","author":"Shirani","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2026.104663_b0455","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jconrel.2024.03.014","article-title":"Supramolecular nanodrug targeting CDK4\/6 overcomes BAG1 mediated cisplatin resistance in oral squamous cell carcinoma","volume":"368","author":"Zhao","year":"2024","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2026.104663_b0460","doi-asserted-by":"crossref","first-page":"7915","DOI":"10.1039\/D2CE01288J","article-title":"Solubility and permeability enhancement of BCS class IV drug ribociclib through cocrystallization","volume":"24","author":"Mannava","year":"2022","journal-title":"CrstEngComm"},{"key":"10.1016\/j.drudis.2026.104663_b0465","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.3390\/polym15132844","article-title":"Ribociclib hybrid lipid\u2013polymer nanoparticle preparation and characterization for cancer treatment","volume":"15","author":"Al-Shdefat","year":"2023","journal-title":"Polymers (Basel)"},{"key":"10.1016\/j.drudis.2026.104663_b0470","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jconrel.2025.02.020","article-title":"Poly(amino acid) nanoformulation of cyclin-dependent kinase 4 and 6 inhibitor for molecularly targeted immunotherapy in triple-negative breast cancer","volume":"380","author":"Wei","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.drudis.2026.104663_b0475","doi-asserted-by":"crossref","first-page":"20628","DOI":"10.1021\/acsami.2c01305","article-title":"Artificial assembled macrophage co-deliver black phosphorus quantum dot and CDK4\/6 inhibitor for colorectal cancer triple-therapy","volume":"14","author":"Fang","year":"2022","journal-title":"ACS Appl Mater Interfaces"},{"key":"10.1016\/j.drudis.2026.104663_b0480","article-title":"Neutrophil-targeted liposomal platform: a shift in novel approach for early detection and treatment of cancer metastasis","volume":"19","author":"Li","year":"2024","journal-title":"Asian J Pharm Sci"},{"key":"10.1016\/j.drudis.2026.104663_b0485","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.ijbiomac.2022.09.026","article-title":"Theranostics platform of abemaciclib using magnetite@silica@chitosan nanocomposite","volume":"221","author":"El-Shahawy","year":"2022","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.drudis.2026.104663_b0490","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202000906","article-title":"Charge and size dual switchable nanocage for novel triple-interlocked combination therapy pattern","volume":"7","author":"Yang","year":"2020","journal-title":"Adv Sci"},{"key":"10.1016\/j.drudis.2026.104663_b0495","first-page":"1","article-title":"Injectable supramolecular hydrogel co-loading abemaciclib\/NLG919 for neoadjuvant immunotherapy of triple-negative breast cancer","volume":"16","author":"Zhu","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2026.104663_b0500","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.jsps.2022.03.019","article-title":"Abemaciclib-loaded ethylcellulose based nanosponges for sustained cytotoxicity against MCF-7 and MDA-MB-231 human breast cancer cells lines","volume":"30","author":"Anwer","year":"2022","journal-title":"Saudi Pharm J"},{"key":"10.1016\/j.drudis.2026.104663_b0505","doi-asserted-by":"crossref","first-page":"18137","DOI":"10.1021\/acsomega.3c10142","article-title":"Lysine-polydopamine nanocrystals loaded with the codrug abemaciclib-flurbiprofen for oral treatment of cancer","volume":"9","author":"Sun","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.drudis.2026.104663_b0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103863","article-title":"Cyclin-dependent kinase 4 and 6 inhibitors (CDK4\/6i): mechanisms of resistance and where to find them","volume":"79","author":"Foffano","year":"2025","journal-title":"Breast"},{"key":"10.1016\/j.drudis.2026.104663_b0515","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102980","article-title":"Overcoming resistance to CDK4\/6 inhibitors in hormone receptor positive, HER2 negative breast cancer: innovative combinations and emerging strategies","volume":"139","author":"Giugliano","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.drudis.2026.104663_b0520","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-025-02305-x","article-title":"Advances in cancer immunotherapy: historical perspectives, current developments, and future directions","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.drudis.2026.104663_b0525","first-page":"1","article-title":"The role of targeting CDK4\/6 in cancer immunotherapy","volume":"3","author":"Sun","year":"2024","journal-title":"Holist Integr Oncol"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000681?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644626000681?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T16:21:59Z","timestamp":1785946919000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644626000681"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":105,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1359644626000681"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104663","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addressing delivery and resistance issues of CDK4\/6 inhibitors as cancer therapeutics","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2026.104663","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104663"}}